Ardelyx Inc is a biopharmaceutical company focused on developing innovative therapies for patients with gastrointestinal and kidney-related diseases
The company is committed to creating targeted treatments that address significant unmet medical needs, leveraging its proprietary platform to discover and advance novel compounds. Ardelyx’s research and development efforts aim to improve the quality of life for patients suffering from conditions such as chronic kidney disease and irritable bowel syndrome, with a focus on delivering effective and safe therapeutic options.
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.
Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment.
